Jorge Pando
Obstetrics & Gynecology · Miami Lakes, FLNPI 1437323219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Intuitive Surgical at 32.7% of the total. Reporting peaked in 2023 at $909 and has fallen 84.2% since, to $144 in 2025.
Across 108 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$940
- Astellas Pharma US Inc$864
- AbbVie$267
- Conmed Corporation$233
- Pfizer$155
- Sumitomo Pharma America, Inc.$122
- plus $291 from 11 others
Across 77 payments — averaging $19,531 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exeltis, USA Inc.$1.4M
- Merck$119K
What the payments were for
- Travel & lodging$201%
- Food & beverage$2,66293%
- Education$1887%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $940 |
| Astellas Pharma US Inc | 45 | $864 |
| AbbVie | 15 | $267 |
| Conmed Corporation | 3 | $233 |
| Pfizer | 7 | $155 |
| Sumitomo Pharma America, Inc. | 5 | $122 |
| Caldera Medical, Inc | 3 | $68 |
| Coloplast | 2 | $33 |
| Axonics, Inc. | 1 | $29 |
| Hologic Sales And Service, LLC | 1 | $27 |
| Davol Inc. | 1 | $26 |
| Avion Pharmaceuticals | 1 | $23 |
| Evofem Biosciences, Inc. | 1 | $21 |
| Exeltis, USA Inc. | 1 | $20 |
| Coopersurgical, Inc. | 1 | $17 |
| Millicent US Inc | 1 | $13 |
| Urovant Sciences Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSEAL$106
- VISICLEAR$106
- Da Vinci Surgical System$100
How this compares
$2,870 in reported general payments places this provider in the 80th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 236 | $118,137 |
| Tolterodine Tartrate ErTolterodine Tartrate | 271 | $45,859 |
| GemtesaVibegron | 49 | $26,512 |
| Mirabegron ErMirabegron | 70 | $21,963 |
| Estradiol | 310 | $20,821 |
| PremarinEstrogens, Conjugated | 54 | $20,293 |
| Oxybutynin Chloride ErOxybutynin Chloride | 401 | $14,281 |
| Solifenacin Succinate | 67 | $9,224 |
| Clindamycin Phosphate | 64 | $4,796 |
| ProgesteroneProgesterone, Micronized | 56 | $3,509 |
| Oxybutynin Chloride | 171 | $3,013 |
| Clobetasol Propionate | 57 | $2,175 |
| Tranexamic Acid | 24 | $1,989 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 122 | $1,273 |
| Fluconazole | 61 | $878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $864 | $118,137236 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $122 | $26,51249 claims |
| PfizerPremarin | $155 | $20,29354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,438 obstetrics & gynecology providers in Florida.
Other obstetrics & gynecology in Miami Lakes
- Steven McCarusCelebration$2.3M
- Elliot CazesTampa$725K
- Charles BloomWinter Park$652K
- Jay CohenPlantation$556K
- Omar ZwainWinter Park$531K
- Keith AquaWellington$473K
- Jeffrey KotzenPalm Beach Gardens$413K
- Glenn BankertCrestview$388K
- Erica StockwellCelebration$321K
- Scott JordanFort Lauderdale$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.